Published in Leukemia on March 01, 2004
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2012) 2.55
Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. J Clin Oncol (2008) 1.83
New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2011) 1.78
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol (2008) 1.75
Status of minimal residual disease testing in childhood haematological malignancies. Br J Haematol (2008) 1.43
Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood (2006) 1.41
Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am (2009) 1.28
Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol (2009) 1.04
Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin North Am (2014) 1.04
Progress of minimal residual disease studies in childhood acute leukemia. Curr Hematol Malig Rep (2010) 1.02
Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting. Haematologica (2009) 1.02
Measurements of treatment response in childhood acute leukemia. Korean J Hematol (2012) 0.84
High-risk childhood acute lymphoblastic leukemia. Clin Lymphoma Myeloma (2009) 0.84
Treating refractory leukemias in childhood, role of clofarabine. Ther Clin Risk Manag (2008) 0.84
Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing. Best Pract Res Clin Haematol (2010) 0.82
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer (2016) 0.82
Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia. Haematologica (2015) 0.79
Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome. Haematologica (2015) 0.79
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia (2004) 0.77
Results of treatment of advanced-stage lymphoblastic lymphoma at St Jude Children's Research Hospital from 1962 to 2002. Ann Oncol (2013) 0.75
Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review. Ont Health Technol Assess Ser (2016) 0.75
Improvement of the Outcome of Relapsed or Refractory Acute Lymphoblastic Leukemia in Children Using a Risk-Based Treatment Strategy. PLoS One (2016) 0.75
Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia? Mol Diagn Ther (2017) 0.75
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet (1999) 3.63
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia (2004) 3.59
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst (1999) 3.58
Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity (1996) 3.33
Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med (1995) 3.26
Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet (1998) 3.07
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood (2000) 2.92
Tretinoin toxicity in children with acute promyelocytic leukaemia. Lancet (1993) 2.85
Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol (2004) 2.63
TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia (1995) 2.54
Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48
Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci U S A (1992) 2.41
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther (2013) 2.40
Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med (1997) 2.38
Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol (2008) 2.37
Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science (1998) 2.31
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24
Myeloid neoplasia in children treated for solid tumours. Lancet (1990) 2.18
Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood (1999) 2.18
Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. N Engl J Med (1996) 2.10
Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys (1995) 2.01
Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med (1993) 1.99
Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther (2013) 1.99
Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia (2000) 1.94
Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood (2000) 1.89
Acute lymphoblastic leukemia in a developing country: preliminary results of a nonrandomized clinical trial in El Salvador. J Pediatr Hematol Oncol (2000) 1.83
Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med (1991) 1.83
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther (2008) 1.82
Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. J Clin Oncol (2001) 1.81
Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood (1991) 1.74
Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med (1989) 1.69
In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A (1992) 1.67
Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia (2004) 1.65
Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. J Clin Oncol (2001) 1.64
Childhood adrenocortical tumors. J Clin Endocrinol Metab (1997) 1.64
Cerebellocerebral diaschisis is the likely mechanism of postsurgical posterior fossa syndrome in pediatric patients with midline cerebellar tumors. AJNR Am J Neuroradiol (2009) 1.64
An essential role for BLNK in human B cell development. Science (1999) 1.64
A novel monoclonal antibody BI-3C5 recognises myeloblasts and non-B non-T lymphoblasts in acute leukaemias and CGL blast crises, and reacts with immature cells in normal bone marrow. Leuk Res (1985) 1.61
Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood (1998) 1.60
Neurocognitive deficits in medulloblastoma survivors and white matter loss. Ann Neurol (1999) 1.59
Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol (2004) 1.57
A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem Biol (1998) 1.55
Mutations in the human lambda5/14.1 gene result in B cell deficiency and agammaglobulinemia. J Exp Med (1998) 1.55
Correlation of pathologic features with clinical outcome in pediatric adrenocortical neoplasia. A study of a Brazilian population. Brazilian Group for Treatment of Childhood Adrenocortical Tumors. Am J Clin Pathol (1994) 1.53
Identification of a tumor necrosis factor-responsive element in the tumor necrosis factor alpha gene. J Biol Chem (1991) 1.52
Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. J Clin Oncol (1998) 1.52
Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med (1987) 1.52
PITSLRE protein kinase activity is associated with apoptosis. Mol Cell Biol (1995) 1.51
Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood (2001) 1.50
M-BCR rearrangement in a case of T-cell childhood acute lymphoblastic leukemia. Med Pediatr Oncol (1999) 1.50
Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest (1996) 1.49
Childhood acute lymphoblastic leukaemia--current status and future perspectives. Lancet Oncol (2001) 1.48
Veno-occlusive disease of the liver after chemotherapy for rhabdomyosarcoma: case report with a review of the literature. Med Pediatr Oncol (1995) 1.47